Kane Biotech Engages Kilmer Lucas for Cross-Border Investor Relations
November 26 2019 - 8:00AM
Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announced that that it
has engaged Kilmer Lucas Inc. (“Kilmer Lucas”) to provide the
Company with select U.S. and Canadian investor relations (“IR”) and
strategic advisory services.
Employing an ‘outsourced in-house’ partnership
model, Kilmer Lucas designs and executes customized IR programs for
healthcare companies.
“Having undergone a company-wide transformation
during the past year, we evaluated a number of IR firms that could
support our continued growth and help us communicate our progress
to a broader investor audience, and upon the recommendation of a
trusted advisor, we selected Kilmer Lucas,” stated Marc Edwards,
CEO of Kane Biotech.
“Kane Biotech continues to execute on its
strategic plan to become a global leader in anti-biofilm
technologies, and we are excited to work with the Company as it
expands its animal health products business and progresses its
first human health product toward commercialization,” commented
Kilmer Lucas’ founder and President, Stephen Kilmer. “Through the
provision of a full range of IR and strategic advisory services,
our primary goals will be to assist Kane Biotech in achieving a
fair and sustainable market valuation and communicate its evolving
growth strategy, as well as its accomplishments, to
stakeholders.”
Kilmer Lucas is an arm's length third party to
Kane Biotech, and it does not have any interest, directly or
indirectly, in Kane Biotech, or any right or intent to acquire such
an interest. Kane Biotech will pay Kilmer Lucas a monthly retainer
fee of $7,500 for its services. The agreement between Kane Biotech
and Kilmer Lucas has an initial term of 90 days, following which
the agreement can be terminated for any reason by either party upon
30 days’ written notice.
About Kilmer Lucas
Kilmer Lucas is the first and only cross-border,
healthcare-focused investor relations and capital markets advisory
firm. It takes a holistic approach to building a customized IR
strategy, that begins with a deep understanding of a company's
corporate and financial goals. Kilmer Lucas seeks to leverage its
longstanding relationships and strong track record to positively
influence investor perceptions, maximize stock valuations and lower
the cost of capital needed to fund its clients' growth. Since 2009,
the firm has also published the popular healthcare investor news
blog and e-letter, BioTuesdays. To-date, BioTuesdays has profiled
more than 450 healthcare companies, providing invaluable exposure
for innovative technologies and compelling investment stories that
may have otherwise gone unnoticed. More information about the firm
can be found at www.kilmerlucas.com.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged
in the research, development and commercialization of technologies
and products that prevent and remove microbial biofilms. The
Company has a portfolio of biotechnologies, intellectual property
(56 patents and patents pending, trade secrets and trademarks) and
products developed by the Company's own biofilm research expertise
and acquired from leading research institutions. StrixNB™,
DispersinB®, bluestem™, AloSera™, coactive+™ and Kane® are
trademarks of Kane Biotech Inc. The Company is listed on the TSX
Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive
OfficerKane Biotech Inc. +1 (514)
910-6991medwards@kanebiotech.com Ray Dupuis Chief Financial
OfficerKane Biotech Inc. +1 (204)
298-2200rdupuis@kanebiotech.com Stephen KilmerInvestor
Relations +1 (646) 274-3580skilmer@kanebiotech.com
|
|
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements
regarding Kane Biotech Inc. that constitute forward-looking
information under applicable securities laws. These statements
reflect management's current beliefs and are based on information
currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
but are not limited to, risks relating to the Company's: (a)
financial condition, including lack of significant revenues to date
and reliance on equity and other financing; (b) business, including
its early stage of development, government regulation, market
acceptance for its products, rapid technological change and
dependence on key personnel; (c) intellectual property including
the ability of the Company to protect its intellectual property and
dependence on its strategic partners; and (d) capital structure,
including its lack of dividends on its Shares, volatility of the
market price of its Shares and public company costs. Further
information about these and other risks and uncertainties can be
found in the disclosure documents filed by the Company with
applicable securities regulatory authorities, available at
www.sedar.com. The Company cautions that the foregoing list of
factors that may affect future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2023 to Apr 2024